Clinical trials: Rectal Cancer, Metastatic
Radiotherapy, Immunotherapy
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
This study is a randomized controlled phase II trial to evaluate the efficacy of the combination of stereotactic body radiation therapy (SBRT) and immunotherapy with postoperative chemotherapy in colorectal cancer liver…
- Conditions
- Radiotherapy, Immunotherapy, Liver Metastases, Colorectal Cancer
- Trial name
- IMPROVE (NCT06120127)
- Testing
- SBRT, Chemotherapy, PD-1 antibody
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer.
- Trial name
- NCT05064059
- Testing
- favezelimab/pembrolizumab, regorafenib, TAS-102
- Where
- 152 sites in United States, Australia and 19 more
- Volunteers
- 441 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Neoplasms, Neoplasms
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Background: Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors are often treated using a hepatic artery infusion (HAI) pump.
- Conditions
- Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma
- Trial name
- NCT07715903
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Lung Cancer
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.
Novel treatment modalities like targeted therapies and Immune checkpoint inhibitors have revolutionised the therapeutic landscape in oncology and hematology, significantly improving outcomes even in clinical contexts in which…
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Head and Neck Cancer
- Trial name
- POSITive (NCT06321640)
- Testing
- Cohort A: primarily operable disease, candidate to adjuvant, Cohort B: locally advanced disease, Cohort C: metastatic disease
- Where
- Italy
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
- Trial name
- NCT07085091
- Testing
- ALX2004
- Where
- 12 sites in United States
- Volunteers
- 170 people
- Sponsor
- ALX Oncology Inc.
Neoplasm Metastasis, Colorectal Neoplasms
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences.
- Trial name
- NCT00037180
- Testing
- Celecoxib, Irinotecan, 5-fluorouracil
- Where
- 12 sites in United States
- Volunteers
- 212 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with metastatic colorectal cancer after failure of second-line and more than…
- Trial name
- NCT01386242
- Testing
- Recombinant anti-tumor and anti-virus protein for injection, Saline Injection
- Where
- China
- Volunteers
- 108 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Gastrointestinal Tumors, Colorectal Adenocarcinomas
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
- Conditions
- Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
- Trial name
- NCT04171141
- Testing
- PF-07062119, Anti-PD1, Anti-VEGF
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
Medical Food for the Dietary Management of Metastatic Colorectal Cancer
This is a single arm study evaluating the tolerability and markers of colorectal cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with metastatic colorectal…
- Trial name
- NCT05183295
- Testing
- NEAAR Medical Food
- Sponsor
- Faeth Therapeutics
Colorectal Cancer
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
The primary objective of this study is to evaluate the efficacy of Irinotecan Beads in combination with intravenous cetuximab versus intravenous irinotecan in combination with intravenous cetuximab in the treatment of patients…
- Trial name
- DEBIRITUX (NCT01060423)
- Testing
- Cetuximab, Irinotecan, Irinotecan eluting BEADS
- Where
- 13 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Hans-Joachim Schmoll, MD
Metastatic Colorectal Cancer
Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.
The purpose of this study is to determine whether bevacizumab, capecitabine and oxaliplatin are an effective and safe first line of treatment for elderly patients with metastatic colorectal adenocarcinoma.
- Trial name
- BECOX (NCT01067053)
- Testing
- bevacizumab, capecitabine, oxaliplatin
- Where
- 15 sites in Spain
- Volunteers
- 69 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Metastatic Colorectal Cancer
Circulating Tumor Cells and Neutrophils Count for Colorectal Metastatic Cancer
Colorectal cancer represents a major public health problem in France because of its high incidence and severe prognosis. Early stages of the disease are well know and have justified the establishment of a mass screening strategy.
- Trial name
- NCT05793775
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Liver Metastases, Mucinous Adenocarcinoma of the Colon
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Conditions
- Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer
- Trial name
- NCT01285102
- Testing
- irinotecan-eluting beads, hepatic artery embolization
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fox Chase Cancer Center
Colorectal Cancer, MSS
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
This is a multi-center, non-randomised Phase 1b study to evaluate the safety and tolerability of ATP128 alone or in combination with BI 754091 and of heterologous prime-boost ATP128 + VSV-GP128 in combination with BI 754091.
- Conditions
- Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- KISIMA-01 (NCT04046445)
- Testing
- ATP128, BI 754091, VSV-GP128
- Where
- 12 sites in United States, Belgium and 2 more
- Volunteers
- 96 people
- Sponsor
- Amal Therapeutics
Colorectal Cancer
Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases
Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases - a Single-center, Single-arm, Open-label Clinical…
- Trial name
- NCT06124729
- Testing
- Bevacizumab Combined With PD-1 Monoclonal Antibody
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Colorectal Cancer, Metastatic to the Liver
Utility of Intra-operative Image Guidance System for Missing Metastases
Intraoperatively, the surgeon will interrogate the liver with ultrasound. The time spent by the surgeon using the ultrasound is recorded.
- Trial name
- NCT02806037
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a…
- Conditions
- Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
- Trial name
- CombiCoR-Vax (NCT06522919)
- Testing
- Autologous Dendritic Cell (DC) Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Colorectal Cancer (CRC), Capecitabine
First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study
This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided…
- Conditions
- Colorectal Cancer (CRC), Capecitabine, Cetuximab
- Trial name
- CAPCET-III (NCT06616259)
- Testing
- mCapOX plus Cetuximab, mFOLFOX6 plus Cetuximab
- Where
- China
- Volunteers
- 452 people
- Sponsor
- Meng Qiu
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.